A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions

Trial Profile

A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel
  • Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT-II
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 19 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jul 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
    • 01 Jun 2011 Four-year follow-up results published in Catheterization and Cardiovascular Interventions.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top